



UNIVERSITY OF LEEDS

This is a repository copy of *EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/155874/>

Version: Supplemental Material

Article:

Smolen, JS, Landewé, RB, Bijlsma, JWJ et al. (44 more authors) (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Annals of the Rheumatic Diseases*. ISSN 0003-4967

<https://doi.org/10.1136/annrheumdis-2019-216655>

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This manuscript version is made available under the CC BY-NC 4.0 license <https://creativecommons.org/licenses/by-nc/4.0/>

Reuse


This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



1. 2010 ACR-EULAR classification criteria can support early diagnosis.

2. "Methotrexate should be part of the first treatment strategy". While combination therapy of csDMARDs is not preferred by the Task Force, starting with methotrexate does not exclude its use in combination with other csDMARDs although more adverse events without added benefit are to be expected, especially if MTX is combined with glucocorticoids.

3. The treatment target is clinical remission according to ACR-EULAR definitions or, if remission is unlikely to be achievable, at least low disease activity; the target should be reached after 6 months, but therapy should be adapted or changed if insufficient improvement (less than 50% of disease activity) is seen after 3 months.

4. Sustained remission: ≥ 6 months ACR/EULAR index based or Boolean remission.

5. Consider contraindications and risks.

6. The most frequently used combination comprises methotrexate, sulfasalazine and hydroxychloroquine.

7. TNF-inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab, including EMA/FDA approved bDMARDs), abatacept, IL-6R inhibitors, or rituximab (under certain conditions); in patients who cannot use csDMARDs as comedication, IL6-inhibitors and tsDMARDs have some advantages.

8. Dose reduction or interval increase can be safely done with all bDMARDs and tsDMARDs with little risk of flares; stopping is associated with high flare rates; most but not all patients can recapture their good state upon re-institution of the same bDMARD/tsDMARD.

9. Efficacy and safety of bDMARDs after JAK-inhibitor failure is not fully known; also, efficacy and safety of an IL-6 pathway inhibitor after another one has failed is currently unknown. Efficacy and safety of a JAK-inhibitor after insufficient response to a previous JAK-inhibitor is unknown.